Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1333 - Meta-analysis of prognostic factors of completely resected pathologic N2 stage IIIA non–small cell lung cancer: including 11,384 patients.

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Xianquan Zhan

Citation

Annals of Oncology (2018) 29 (suppl_8): viii488-viii492. 10.1093/annonc/mdy291

Authors

X. Zhan, N. Li

Author affiliations

  • Key Laboratory Of Cancer Proteomics Of Chinese Ministry Of Health, Xiangya Hospital, Central South University, 410008 - Changsha/CN
More

Resources

Abstract 1333

Background

Patients with IIIA-pN2 non-small cell lung cancer (NSCLC) are a heterogeneous group, So this meta-analysis aimed to determine prognostic factors and compare different postoperative adjuvant therapies on survival.

Methods

MEDLINE, Embase, Web of Science were searched to identify relevant trials up to May 2017. Datas of univariate and multivariate analyses of prognostic factors for overall survival (OS) were extracted and calculated by hazard ratios (HR) and 95% confience intervals (95% CI). Pooled survival curves were constructed by Engauge Digitizer and RStudio.

Results

Overall 26 trials comprising 11,384 patients were included. The subgroup analysis for OS indicated that increased age (HR 1.02, 95%CI 1.02-1.02, P < 0.00001), male (HR 1.37, 95%CI 1.25–1.49, P < 0.00001), increased pathologic T stage (HR 1.27, 95%CI 1.12–1.45, P = 0.0003), multiple N2 metastases (HR 1.53, 95%CI 1.34–1.74, P < 0.0001), positive of skip matestasis (HR 2.07, 95%CI 1.25–3.42, P < 0.0001), involvement of N1 nodal station (HR 1.42, 95%CI 1.13–1.70, P = 0.003), pneumonectomy (HR 1.42, 95%CI 1.16–1.73, P = 0.0007), increasing clinical T classification (HR 1.48, 95%CI 1.09–2.02, P = 0.01), increasing clinical N classification (HR 1.75, 95%CI 1.23–1.48, P = 0.002) were significantly associated with poor OS and N downstaging (HR 0.46, 95%CI 0.37–0.68, P < 0.0001), PORT (HR 0.76, 95%CI 0.64–0.72, P = 0.004), adjuvant chemotherapy (HR 0.69, 95%CI 0.56–0.85, P = 0.007) were significantly associated with better OS. The 5-year disease-free survival rate was 38.9% in postoperative chemoradiotherapy group and 29.5% in postoperative chemotherapy group (p = 0.001). Survival was improved in patients with pN2 disease who received postoperative radiotherapy, both in the chemotherapy (5-year survival rate, 65.3% vs. 49.3%) and observation arm (5-year survival rate, 53.3% vs. 32.3%).

Conclusions

The main prognostic factors were age, gender, clinical T stage, pathologic T stage, operation procedure, clinical N status, involved N2 stations, N1 nodes involved, N2 Skip metastasis, N downstaging, postoperative radiotherapy as well as adjuvant chemotherapy. And these should be considered as stratification factors for further trials.

Clinical trial identification

Legal entity responsible for the study

Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University.

Funding

China “863” Plan Project.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.